10-Q: Nkarta Shifts Focus to Autoimmune, Cuts Workforce

Nkarta, Inc. reported continued net losses in Q2 2025, alongside a strategic pivot to prioritize autoimmune disease programs and a significant workforce reduction.

Summary

• Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies, primarily focusing on autoimmune diseases.
• The company reported a net loss of $22.977 million for the three months ended June 30, 2025, an improvement from a $24.993 million net loss in the same period of 2024.
• For the six months ended June 30, 2025, the net loss was $54.960 million, slightly higher than the $54.511 million loss for the same period in 2024.
• Research and development expenses decreased by $2.352 million to $20.778 million for the three months ended June 30, 2025, and by $3.417 million to $44.950 million for the six months, primarily due to lower personnel costs from a workforce reduction.
• General and administrative expenses increased by $3.690 million to $18.800 million for the six months ended June 30, 2025, largely due to $5.1 million in severance expenses from the March 2025 reduction in force.
• As of June 30, 2025, Nkarta had $334.0 million in cash, cash equivalents, restricted cash, and investments.
• The company announced a reduction in force in March 2025, cutting 53 positions (approximately 34% of its workforce) to decrease costs and streamline operations.
• Strategic focus has shifted to NKX019 for autoimmune diseases, with primary membranous nephropathy (pMN) added as an indication to the Ntrust-1 clinical trial (for lupus nephritis 'LN').
• Lymphodepleting conditioning for Ntrust-1 and Ntrust-2 clinical trials was modified to use a combination of fludarabine (Flu) and cyclophosphamide (Cy).
• Investigator-sponsored trials (ISTs) for NKX019 in myasthenia gravis (MG) and systemic lupus erythematosus (SLE) have been initiated.
• Development of NKX019 for B-cell malignancies and NKX101 for hematologic malignancies has been deprioritized.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the company is taking steps to manage costs (workforce reduction) and strategically focusing its pipeline on autoimmune diseases, it continues to incur significant losses and has deprioritized two oncology programs. The need for substantial future capital and ongoing clinical trial challenges contribute to a cautious outlook, despite the potential of its core technology.

Positives

• Net loss for the three months ended June 30, 2025, improved to $22.977 million from $24.993 million in the prior year period.
• Net cash used in operating activities decreased to $48.365 million for the six months ended June 30, 2025, from $50.400 million in the prior year, indicating improved cash management.
• Net cash provided by investing activities significantly improved to $73.829 million for the six months ended June 30, 2025, compared to cash used of $86.140 million in the prior year, driven by maturities of marketable securities.
• The company has $334.0 million in cash, cash equivalents, restricted cash, and investments as of June 30, 2025, which management believes is sufficient for at least 12 months.
• Strategic decision to focus resources on NKX019 for autoimmune diseases, including new indications like primary membranous nephropathy (pMN), aims to streamline development and maximize success.
• Appointment of Shawn Rose, M.D. Ph.D as Chief Medical Officer and Head of Research and Development strengthens leadership in key areas.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $599.184 million as of June 30, 2025.
• Net loss for the six months ended June 30, 2025, worsened slightly to $54.960 million compared to $54.511 million in the prior year.
• General and administrative expenses increased by $3.690 million for the six months ended June 30, 2025, primarily due to $5.1 million in severance costs from the workforce reduction.
• Interest income decreased due to lower average investment balances and lower average interest rates.
• The company has deprioritized the clinical development of NKX019 for B-cell malignancies and the NKX101 program for hematologic malignancies, indicating setbacks or strategic shifts away from previous focus areas.
• Patient enrollment and retention in clinical trials, particularly for autoimmune diseases, have been and may continue to be challenging due to competition and the novelty of cell therapy for these conditions.

Risks

• The company has a limited operating history and no products approved for sale, with significant losses incurred since inception and expected to continue.
• Additional capital will be required to fund operations, which may cause dilution to stockholders or restrict operations.
• The business is highly dependent on the success of its novel CAR NK-cell technology platform, which is largely unproven for commercial use.
• Clinical development is a lengthy, expensive, and uncertain process, with potential for substantial delays due to factors outside the company's control.
• Clinical data supporting the effectiveness of CD19-targeted cell therapies against autoimmune diseases are limited, and NKX019 may not provide the same therapeutic benefit or be competitive.
• Enrollment and retention of patients in clinical trials are expensive, time-consuming, and subject to multiple factors outside the company's control, including competition from other trials.
• Certain aspects of CAR NK cell function and production are unknown or poorly understood, potentially requiring re-engineering, delays, and additional expenses.
• Results of preclinical studies and early-stage clinical trials may not be predictive of future results, and interim data may differ materially from final data.
• Serious adverse events from product candidates or competing products could halt or delay further clinical development.
• The company faces intense competition from academic institutions and other biopharmaceutical companies developing similar or alternative cellular immunotherapy product candidates.
• The manufacturing process is novel and complex, with potential difficulties in production or internal manufacturing, which could delay supply for clinical trials or commercialization.
• Reliance on third parties for manufacturing certain materials increases the risk of insufficient quantities or unacceptable costs.
• The company is reliant on a sole supplier (Miltenyi) for certain critical steps and reagents in its manufacturing process, posing supply chain risks.
• Delays in commissioning and receiving regulatory approvals for manufacturing facilities could delay development plans.
• Optimal donor and manufacturing parameters for product candidates have not been definitively established, hindering optimization and addressing safety/efficacy issues.
• Termination of the license agreement with National University of Singapore and St. Jude Children's Research Hospital, Inc. could lead to loss of rights to key NK-cell engineering platform components.
• Patent protection may not be sufficiently robust, allowing competitors to develop similar products.
• Claims for infringing third-party intellectual property rights could be costly and delay commercialization.
• Failure to establish marketing, sales, and distribution capabilities will prevent successful commercialization if products are approved.
• Approved product candidates could be subject to regulatory limitations post-approval, affecting market acceptance and revenue.
• The market price for common stock may be volatile, and concentration of ownership may prevent new investors from influencing corporate decisions.
• Computer system interruptions or security breaches could disrupt product development and business operations.
• Macroeconomic conditions, including rising inflation, interest rates, and supply chain constraints, could adversely affect the business.
• The misuse of artificial intelligence could adversely impact the business, including posing security risks to confidential information.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it develops and seeks regulatory approvals for product candidates, expands its pipeline, maintains intellectual property, and builds commercial capabilities. Future operating expenses are expected to increase substantially. Management believes current cash and investments are sufficient for at least 12 months from the filing date, but additional funding will be required through equity, debt, or collaborations. The company plans to conduct additional clinical trials in less heavily pretreated patient populations to expand market opportunities for NKX019, if initial trials show sufficient efficacy.

Management Comments

• Management approved a reduction in workforce in March 2025 to decrease costs and create a more streamlined organization to support operations and a reprioritized product pipeline.
• The company expects operating expenses to significantly increase in the future as it continues to develop and seek regulatory approvals for product candidates, expand its pipeline, maintain intellectual property, and establish a commercial organization.
• Management believes that current cash, cash equivalents, restricted cash, and investments will provide sufficient funds to meet obligations for at least twelve months from the filing date of this report.

Industry Context

Nkarta operates in the highly competitive and rapidly evolving field of cellular immunotherapy, specifically focusing on allogeneic, off-the-shelf NK cell therapies. The shift to autoimmune diseases, particularly CD19-targeted therapies, places Nkarta in a nascent but increasingly competitive area, as no cell therapies have yet been approved by the FDA for autoimmune conditions. The company faces competition from numerous biopharmaceutical companies and academic institutions developing various approaches, including other cell therapies, T-cell engagers, NK-cell engagers, and monoclonal antibodies. The novelty of cell therapy for autoimmune diseases presents unique regulatory and patient enrollment challenges, as patients in these indications may have a lower tolerance for adverse events compared to oncology patients.

Comparison to Industry Standards

• No cell therapies have been approved by the FDA for the treatment of autoimmune diseases to date, making Nkarta's approach novel and without direct commercial benchmarks.
• The company's decision to deprioritize NKX019 for B-cell malignancies and NKX101 for hematologic malignancies reflects the highly competitive landscape in oncology cell therapies, where established players and numerous clinical trials exist.
• Nkarta's allogeneic, off-the-shelf approach aims to broaden patient access compared to autologous cell therapies (e.g., CAR T-cell therapies like Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti), which are patient-specific and require complex, time-consuming manufacturing.
• The company's use of modified lymphodepleting conditioning (Flu/Cy) is a common practice in cell therapy to enhance engraftment, aligning with industry standards for optimizing cell therapy efficacy.
• The challenges in patient enrollment for autoimmune clinical trials are noted as a broader industry issue due to the newness of cell therapy in this area and competition for sites and patients among companies like Kyverna Therapeutics, Cabaletta Bio, and others exploring CD19-targeted therapies for autoimmune conditions.

Management Changes

Legal Proceedings

• No claims or actions pending against the company that are likely to have a material adverse effect on its business, results of operations, financial condition, or growth prospects.

Stakeholder Impact

• Shareholders face continued dilution risk due to the need for future capital raises.
• Employees experienced a significant workforce reduction (34% of workforce), which may impact morale and retention.
• Patients with autoimmune diseases may benefit from the company's focused development of NKX019, but face risks of clinical trial delays or inconclusive results.
• Suppliers and creditors may face risks related to the company's ongoing losses and reliance on external funding.

Next Steps

• Continue clinical development of NKX019 for lupus nephritis (LN) and primary membranous nephropathy (pMN) in the Ntrust-1 clinical trial.
• Continue clinical development of NKX019 for systemic sclerosis (scleroderma), idiopathic inflammatory myopathy (myositis), and ANCA-associated vasculitis (AAV) in the Ntrust-2 clinical trial.
• Support investigator-sponsored trials (ISTs) of NKX019 in myasthenia gravis (MG) and systemic lupus erythematosus (SLE).
• Continue efforts to scale up and optimize manufacturing processes across the NK-cell engineering platform.
• Work to fully qualify the commercial-scale manufacturing facility.
• Seek additional funding through equity offerings, debt financings, or collaborations/partnerships to support ongoing operations and long-term development strategy.
• Evaluate the impact of the 2025 Reconciliation Act on financial statements and related disclosures.
• Evaluate the impact of ASU 2024-03 on financial statements and related disclosures.

Key Dates

Recommendation

Nkarta is a clinical-stage biopharmaceutical company with a novel CAR NK-cell therapy platform. While the strategic pivot to autoimmune diseases and cost-containment measures are positive steps, the company continues to incur significant net losses and has deprioritized two oncology programs, indicating high development risk. The need for substantial future capital raises and ongoing clinical trial enrollment challenges create uncertainty. A 'hold' recommendation is appropriate for seasoned investors, acknowledging the long-term potential of the technology but also the significant financial and clinical hurdles that remain before profitability can be achieved.

Keywords

NK cell therapy, CAR NK, Autoimmune disease, Lupus nephritis, Primary membranous nephropathy, Systemic sclerosis, Idiopathic inflammatory myopathy, ANCA-associated vasculitis, Biopharmaceutical, Clinical-stage, Off-the-shelf, Allogeneic, NKX019, SEC filing, 10-Q